Literature DB >> 3582423

The biotransformation of thioridazine to thioridazine 5-sulfoxide stereoisomers in phenobarbital induced rats.

P W Hale, A Poklis.   

Abstract

The disposition and urinary elimination of thioridazine 5-sulfoxide (ring sulfoxide) following subacute administration of thioridazine was investigated in control and phenobarbital (Pb) induced rats. The ring sulfoxide exists as two stereoisomeric pairs, identified by high performance liquid chromatography as fast eluting (RSF) and slow eluting (RSS) ring sulfoxide. No major differences were detected in the distribution in serum or tissue of the ring sulfoxide between control and induced animals. The ring sulfoxide accumulated in all tissues studied. RSF tissue concentrations were significantly greater than those of RSS in both groups. However, stereoselective formation and elimination of the two ring sulfoxides was not noted in either group. Pb inducible cytochrome P-450 drug metabolizing enzymes do not appear to play a major role in the biotransformation of thioridazine to the ring sulfoxide.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3582423     DOI: 10.1007/BF03189113

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  28 in total

1.  Plasma levels and half lives of thioridazine and some of its metabolites. I. High doses in young acute schizophrenics.

Authors:  F A Vanderheeren; R G Muusze
Journal:  Eur J Clin Pharmacol       Date:  1977-01-03       Impact factor: 2.953

2.  Quantitative determination of thioridazine and nonconjugated thioridazine metabolites in serum and urine of psychiatric patients.

Authors:  E Mårtensson; G Nyberg; R Axelsson; K Serck-Hansen
Journal:  Curr Ther Res Clin Exp       Date:  1975-11

3.  A pilot of plasma thioridazine and metabolites in chronically treated patients.

Authors:  A S Papadopoulos; T G Chand; J L Crammer; S Lader
Journal:  Br J Psychiatry       Date:  1980-06       Impact factor: 9.319

4.  Measurement of thioridazine in blood and urine.

Authors:  C H Ng; J L Crammer
Journal:  Br J Clin Pharmacol       Date:  1977-04       Impact factor: 4.335

5.  Thioridazine 5-sulfoxide diastereoisomers in serum and urine from rats and man after chronic thioridazine administration.

Authors:  P W Hale; A Poklis
Journal:  J Anal Toxicol       Date:  1985 Sep-Oct       Impact factor: 3.367

6.  Red blood cell and plasma levels of thioridazine and mesoridazine in schizophrenic patients.

Authors:  A Shvartsburd; V Nwokeafor; R C Smith
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

7.  The effects of thioridazine on electrical and ischemic ventricular fibrillation in the dog heart in situ.

Authors:  J C Davis; J T Bigger
Journal:  J Pharmacol Exp Ther       Date:  1981-01       Impact factor: 4.030

8.  Species differences in pulmonary N-oxidation of chlorpromazine and imipramine.

Authors:  Y Ohmiya; H M Mehendale
Journal:  Pharmacology       Date:  1984       Impact factor: 2.547

9.  Thioridazine and its metabolites in post mortem blood, including two stereoisomeric ring sulfoxides.

Authors:  A Poklis; C E Wells; E C Juenge
Journal:  J Anal Toxicol       Date:  1982 Sep-Oct       Impact factor: 3.367

10.  Thioridazine-induced torsade de pointes. Successful therapy with isoproterenol.

Authors:  A J Kemper; R Dunlap; D A Pietro
Journal:  JAMA       Date:  1983-06-03       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.